Orient announced that the company participated in the bidding process for the 12th batch of centralized national drug procurement. Enzalumide tablets and didrogestrel tablets will be selected for the 12th batch of centralized volume procurement. The procurement period starts on the date of implementation of the selection results and ends on December 31, 2029. In 2025, the company's domestic sales amount of didroprogesterone tablets was about 184 million yuan, accounting for 10.86% of the 2025 revenue.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.